PDCD1 and plasma cell myeloma: Moreover, we took advantage of three PD-1 and/or PD-L1 intervention cohorts, an advanced renal cell carcinoma (RCC) Checkmate cohort, GSE91061 (non-small-cell lung cancer (NSCLC), and GSE135222 (myeloma), to determine whether the m5C score could predict the therapy response in different solid cancers.